KPV vs Larazotide

KPV and Larazotide represent divergent approaches to modulating gut health in research. KPV, a tripeptide derived from α-MSH, leverages anti-inflammatory and antimicrobial actions via NF-κB suppression and PepT1-mediated transport, which is upregulated during gut inflammation—a self-targeting mechanism that enhances its local efficacy. In contrast, Larazotide is a synthetic octapeptide designed to regulate tight junctions and reduce intestinal permeability, primarily studied as an oral adjunct for celiac disease. Their evidence bases differ markedly: KPV is supported by preclinical studies and was among peptides removed from FDA Category 2 in 2026, while Larazotide has advanced through Phase II and III clinical trials. Researchers must weigh these factors when designing studies on intestinal inflammation, barrier function, or immune modulation.

KPV (Lys-Pro-Val, MW ~342.4 g/mol) is a naturally occurring tripeptide derived from the C-terminal region of α-MSH, retaining potent anti-inflammatory and antimicrobial properties without activating melanocortin receptors linked to pigmentation or sexual arousal. Its mechanism involves suppressing NF-κB activation, a key inflammatory pathway, and it is transported into intestinal epithelial cells via the PepT1 transporter, which is upregulated during gut inflammation—creating a self-targeting effect that enhances its local action. This small size facilitates oral bioavailability, unusual for peptides. Preclinical studies indicate KPV reduces intestinal inflammation and supports wound healing, but no formal human safety trials have been conducted. It was among 12 peptides removed from FDA Category 2 on April 15, 2026, reflecting regulatory shifts. Key research applications include gut health and immune support.

Larazotide (AT-1001) is a synthetic 8-amino acid peptide that acts as a tight junction regulator, designed to reduce intestinal permeability triggered by gluten exposure in celiac disease. It is the first drug in its class and has completed Phase II clinical trials and a Phase III trial (INN-202, also called CeDLara), with development by Alba Therapeutics and later 9 Meters Biopharma. Larazotide works locally in the gut lumen without significant systemic absorption, minimizing off-target effects. Evidence from clinical trials indicates it reduces symptoms of celiac disease during gluten exposure and is well tolerated, with adverse event rates similar to placebo. However, its mechanism is specific to tight junction modulation, limiting broader applications compared to KPV. Key claims include reducing intestinal permeability and supporting celiac disease management.

Both peptides are studied for gut health, but their specific research contexts diverge. KPV is also investigated for immune support, leveraging its anti-inflammatory and antimicrobial properties in models of intestinal inflammation, wound healing, and skin health. Larazotide is primarily researched for celiac disease, focusing on gluten-induced permeability and barrier function. While both target the gut, KPV’s broader anti-inflammatory profile suits studies on general gut inflammation, whereas Larazotide’s tight junction regulation is more relevant to permeability disorders. Researchers should select based on whether their model requires inflammation modulation (KPV) or barrier-specific interventions (Larazotide).

KPV has no significant adverse effects reported in preclinical studies, and it does not cause skin darkening unlike Melanotan peptides, due to its lack of melanocortin receptor activation. However, no formal human safety trials have been conducted, limiting translational confidence. Larazotide is well tolerated across Phase I, II, and III trials, with adverse event rates similar to placebo and no significant systemic absorption at therapeutic doses, supporting its safety profile for oral administration. Researchers should note that KPV’s safety data are preclinical, while Larazotide’s clinical evidence provides stronger human safety context, though both are investigational.